Evidence map›Paper›PMID 21152937›Full record

ReviewPediatric nephrology (Berlin, Germany)2011

Clinical and molecular insights into tuberous sclerosis complex renal disease.

Brian J Siroky, Hong Yin, John J Bissler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Tuberous sclerosis complex: the past and the future.Pediatric nephrology (Berlin, Germany) · 2015
    Review
  12. Review
  13. Review
  14. Article
  15. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.American journal of physiology. Renal physiology · 2012
    Article
  16. Tuberous sclerosis complex renal disease.Nephron. Experimental nephrology · 2011
    Review
  17. Clinically relevant imaging in tuberous sclerosis.Journal of clinical imaging science · 2011
    Article
  18. Benign Renal Tumors in Pediatric Age Group: Retrospective Analysis.Journal of Indian Association of Pediatric Surgeons
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brian J SirokyDivision of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, MLC 7022, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA.
Hong Yin
John J Bissler

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with tuberous sclerosis complex are at great risk of developing renal lesions as part of their disease. These lesions include renal cysts and tumors. Significant advances in understanding the cell biology of these renal lesions has already led to clinical trials demonstrating that pharmacological interventions are likely possible. This review focuses on the pathology of these renal lesions, their underlying cell biology, and the possible therapeutic strategies that may prove to significantly improve care for these patients.

Indexed as

AngiomyolipomaAntibiotics, AntineoplasticChildHumansKidney Diseases, CysticKidney NeoplasmsMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProteinsSirolimusTOR Serine-Threonine KinasesTuberous SclerosisAntibiotics, AntineoplasticMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProteinsSirolimusTOR Serine-Threonine Kinases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.